Clinical Trials Logo

CTCL clinical trials

View clinical trials related to CTCL.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02757248 Withdrawn - PTCL Clinical Trials

Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is a phase I study of the combination of volasertib and romidepsin in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) or stage IIB-IV cutaneous T cell lymphoma (CTCL). This study will determine the maximum tolerated dose (MTD) of this combination by treating cohorts of patients at a certain dose combination. The investigators will use a Bayesian design to determine the dose combination for the next cohort of patients and to determine the MTD. Overall response rate as well as adverse events will be monitored and reported.